Latest Articles
- Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk
Prasugrel (Effient) is faster and more consistent in its effects, but patients at high bleeding risk should still receive clopidogrel (Plavix).
- An algorithm for managing warfarin resistance
Some patients need higher-than-expected doses of warfarin to reach their target INR. The cause can be acquired (poor compliance, drug interactions) or hereditary.
- Low bone density is not always bisphosphonate deficiency
Low bone density is not a one-size-fits-all disorder. We need to carefully consider the diagnostic and therapeutic options before assuming that low bone density is osteoporosis.
- Treating the renal patient who has a fracture: Opinion vs evidence
The patient with chronic renal disease who has a fracture remains a unique management challenge. Opinions on treatment abound, but without adequate evidence to back them up.
Acute pancreatitis: Problems in adherence to guidelinesEvidence-based guidelines on managing acute pancreatitis are available, but many physicians are not following them.
- Dual antiplatelet therapy in coronary artery disease: A case-based approach
Many patients need the combination of aspirin and clopidogrel (Plavix) or prasugrel (Effient) to reduce their risk of cardiovascular events, as shown in recent trials.
- Pleural effusion from a candy wrapper
A 60-year-old man presents with worsening shortness of breath and productive cough. Flexible bronchoscopy reveals the surprising cause.